The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Angiotensin converting enzyme inhibitors remain the first treatment of choice

  • Oh, Pyung Chun (Division of Cardiology, Department of Internal Medicine, Heart Center, Gachon University Gil Medical Center) ;
  • Sakuma, Ichiro (Cardiovascular Medicine, Hokko Memorial Clinic) ;
  • Hayashi, Toshio (Department of Geriatrics, Nagoya University Graduate School of Medicine) ;
  • Koh, Kwang Kon (Division of Cardiology, Department of Internal Medicine, Heart Center, Gachon University Gil Medical Center)
  • Received : 2016.02.08
  • Accepted : 2016.02.19
  • Published : 2016.03.01
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-2619. https://doi.org/10.1093/eurheartj/ehs215
  2. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362-e425. https://doi.org/10.1161/CIR.0b013e3182742cf6
  3. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006;114:838-854. https://doi.org/10.1161/CIRCULATIONAHA.105.594986
  4. Tsuyuki RT, McDonald MA. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation 2006;114:855-860. https://doi.org/10.1161/CIRCULATIONAHA.105.594978
  5. Lee JH, Bae MH, Yang DH, et al. Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction. Korean J Intern Med 2016;31:267-276. https://doi.org/10.3904/kjim.2014.268
  6. Yang JH, Hahn JY, Song YB, et al. Angiotensin receptor blocker in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function: prospective cohort study. BMJ 2014;349:g6650. https://doi.org/10.1136/bmj.g6650
  7. Koh KK, Quon MJ, Han SH, Chung WJ, Kim JA, Shin EK. Vascular and metabolic effects of candesartan: insights from therapeutic interventions. J Hypertens Suppl 2006;24:S31-S38.
  8. Koh KK, Oh PC, Quon MJ. Does reversal of oxidative stress and inflammation provide vascular protection? Cardiovasc Res 2009;81:649-659.
  9. Koh KK, Bui MN, Hathaway L, et al. Mechanism by which quinapril improves vascular function in coronary artery disease. Am J Cardiol 1999;83:327-331. https://doi.org/10.1016/S0002-9149(98)00862-5
  10. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-1178. https://doi.org/10.1016/0140-6736(92)92889-N
  11. Bosch J, Lonn E, Pogue J, et al. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005;112:1339-1346. https://doi.org/10.1161/CIRCULATIONAHA.105.548461
  12. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012;33:2088-2097. https://doi.org/10.1093/eurheartj/ehs075
  13. Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003;42:905-910. https://doi.org/10.1016/S0735-1097(03)00846-5
  14. Kim JW, Yun KH, Kim EK, et al. Effect of high dose rosuvastatin loading before primary percutaneous coronary intervention on infarct size in patients with ST-segment elevation myocardial infarction. Korean Circ J 2014;44:76-81. https://doi.org/10.4070/kcj.2014.44.2.76
  15. Lim S, Sakuma I, Quon MJ, Koh KK. Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality. Int J Cardiol 2013;167:1696-1702. https://doi.org/10.1016/j.ijcard.2012.10.037
  16. Koh KK, Sakuma I, Hayashi T, Kim SH, Chung WJ. Renin-angiotensin system inhibitor and statins combination therapeutics: what have we learnt? Expert Opin Pharmacother 2015;16:949-953. https://doi.org/10.1517/14656566.2015.1019464
  17. Koh KK, Quon MJ, Han SH, et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005;45:1088-1093. https://doi.org/10.1161/01.HYP.0000166722.91714.ba
  18. Koh KK, Lim S, Choi H, et al. Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia. Diabetes 2013;62:3547-3552. https://doi.org/10.2337/db13-0566
  19. Jang JY, Lee SH, Kim BS, et al. Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients. Korean Circ J 2015;45:225-233. https://doi.org/10.4070/kcj.2015.45.3.225

Cited by

  1. Combining Potent Statin Therapy with Other Drugs to Optimize Simultaneous Cardiovascular and Metabolic Benefits while Minimizing Adverse Events vol.47, pp.4, 2016, https://doi.org/10.4070/kcj.2016.0406